Hyperemesis Gravidarum at 6 Weeks Pregnant
Hyperemesis gravidarum (HG) is a severe form of pregnancy nausea and vomiting causing significant dehydration, weight loss, and malnutrition. It affects 0.3–3% of pregnancies and often requires medical treatment.
👶 What's Happening at Week 6
Your baby is now the size of a lentil.
- Facial features begin forming — dark spots where eyes will be, openings for nostrils.
- The jaw, cheeks, and chin are taking shape.
- Tiny fingers and toes start to form from the limb buds.
🔬 Why You're Experiencing Hyperemesis Gravidarum at Week 6
- Extreme sensitivity to hCG hormone — associated with high hCG levels (twins, molar pregnancy increase risk)
- Genetic component — runs in families
- Thyroid hormone fluctuations linked to high hCG levels
- Helicobacter pylori infection possibly linked to HG severity
- Psychological factors may influence severity but do not cause HG
💊 Relief Tips for Week 6
📋 Other Week 6 Symptoms
⚠️ Call Your Doctor If…
- Vomiting more than 3–4 times per day with inability to keep fluids down
- Signs of dehydration: dark urine, dizziness, confusion, dry mouth, not urinating
- Weight loss of more than 5% of pre-pregnancy body weight
- Vomiting blood or coffee-ground material
Frequently Asked Questions
How is hyperemesis gravidarum different from morning sickness?
Morning sickness involves nausea and some vomiting but allows adequate hydration and nutrition. HG is defined by persistent severe vomiting causing dehydration, weight loss (>5%), electrolyte imbalance, and inability to function.
Will my baby be affected by hyperemesis gravidarum?
With proper treatment, most babies born to mothers with HG do well. Severe untreated HG with significant malnutrition can affect birth weight.
When does hyperemesis gravidarum end?
For many women, HG improves by weeks 14–20. However, some women experience symptoms throughout their entire pregnancy.
Is Zofran (ondansetron) safe in pregnancy?
Ondansetron is widely used for HG. Current evidence does not confirm increased risk of birth defects, though some earlier studies raised concerns. The decision balances the risks of HG (dehydration, malnutrition) against any potential medication risk.